Marksans Pharma

Which are the latest news on Marksans Pharma?

Why is Marksans Pharma Ltd falling/rising?

As of 05-Sep, Marksans Pharma Ltd's stock is experiencing a decline of 1.61%, following a trend of underperformance and consecutive falls over the past two days. Despite this short-term downturn, the stock has shown significant long-term gains, with an 81.21% increase year-to-date and a 90.68% rise over the past year.

As of 05-Sep, Marksans Pharma Ltd's stock price is currently falling, with a change of -5.35, representing a decline of 1.61%. This decrease follows a trend where the stock has underperformed its sector by 0.6% today and has experienced consecutive falls over the last two days, accumulating a total decline of 1.26% during this period. The stock reached an intraday low of Rs 323.35, reflecting a drop of 2.55%.<BR><BR>Despite the recent downturn, the stock has shown strong performance over longer periods, with a year-to-date increase of 81.21% and a remarkable 90.68% rise over the past year. However, the current decline may be attributed to short-term market fluctuations and the stock's recent performance relative to its moving averages, as it is trading above all key moving averages (5-day, 20-day, 50-day, 100-day, and 200-day).<BR><BR>Additionally, while there has been rising investor participation, with delivery volume increasing by 8.81% against the 5-day average, the stock's recent price action indicates a lack of momentum in the short term. The company's high management efficiency and net-debt-free status, along with positive financial results, suggest a solid long-term outlook, but the current price movement reflects immediate market conditions rather than fundamental weaknesses.

Who are in the management team of Marksans Pharma?

The management team of Marksans Pharma includes Mark Saldanha (Chairman & Managing Director), Harshavardhan Panigrahi (Company Secretary), and several other directors, both executive and independent, who guide the company's strategic direction and ensure regulatory compliance.

The management team of Marksans Pharma includes the following key individuals:<BR><BR>1. **Mark Saldanha** - Chairman & Managing Director<BR>2. **Harshavardhan Panigrahi** - Company Secretary & Compliance Officer<BR>3. **Seetharama Raju Buddharaju** - Non-Executive & Independent Director<BR>4. **Sandra Saldanha** - Whole-time Director<BR>5. **Digant Mahesh Parikh** - Non-Executive & Independent Director<BR>6. **Varddhman Vikramaditya Jain** - Whole-time Director<BR>7. **Abhinna Sundar Mohanty** - Non-Executive & Independent Director<BR>8. **Sunny Sharma** - Director<BR>9. **Shailaja Vardhan** - Independent Director<BR><BR>This team plays a crucial role in guiding the company's strategic direction and ensuring compliance with regulatory requirements.

What does Marksans Pharma do?

Marksans Pharma Ltd is a small-cap company engaged in the research, manufacture, marketing, and sale of pharmaceutical formulations. As of June 2026, it reported net sales of 841 Cr and a net profit of 157 Cr.

Overview: <BR>Marksans Pharma Ltd is engaged in the research, manufacture, marketing, and sale of pharmaceutical formulations within the Pharmaceuticals & Biotechnology industry, classified as a Small Cap company.<BR><BR>History: <BR>Marksans Pharma Limited was incorporated in April 1982 as Tasc Pharmaceuticals Limited. The company underwent a name change to Marksans Pharma Limited effective October 10, 2005, following a Scheme of Amalgamation. The latest reported quarterly results indicate net sales and net profit for June 2026.<BR><BR>Financial Snapshot: <BR>- Net Sales: 841 Cr (Quarterly Results - Jun 2026) <BR>- Net Profit: 157 Cr (Quarterly Results - Jun 2026) <BR>- Market Cap: INR 14,402 Cr (Small Cap) <BR><BR>Key Metrics: <BR>- P/E: 28.00 <BR>- Industry P/E: 37 <BR>- Dividend Yield: 0.27% <BR>- Debt Equity: -0.21 <BR>- Return on Equity: 13.82% <BR>- Price to Book: 4.94 <BR><BR>Contact Details: <BR>Address: 11th Flr GRANDEUR Oshiwara, Veera Desai Extn Rd Andheri(W) Mumbai Maharashtra : 400053 <BR>Tel: 91-22-40012000 <BR>Email: companysecretary@marksanspharma.com <BR>Website: http://www.marksanspharma.com

Who are the peers of the Marksans Pharma?

Peers of Marksans Pharma include Alivus Life, Cohance Life, Alembic Pharma, Concord Biotech, Natco Pharma, Jubilant Pharmo, Akums Drugs, and Viyash Scientifi. Marksans Pharma has a 1-year return of 91.38%, outperforming some peers but underperforming others like Alivus Life.

Peers: The peers of Marksans Pharma are Alivus Life, Cohance Life, Alembic Pharma, Concord Biotech, Natco Pharma, Jubilant Pharmo, Akums Drugs, and Viyash Scientifi.<BR><BR>Quality Snapshot: Excellent management risk is observed at Alivus Life, Alembic Pharma, Concord Biotech, Natco Pharma, and Marksans Pharma, while Average management risk is found at Cohance Life and Jubilant Pharmo, and Average management risk is also noted at Akums Drugs. Below Average management risk is present at Viyash Scientifi. All peers exhibit Below Average growth, except for Akums Drugs, which has Average growth, and Viyash Scientifi, which shows Good growth. Excellent capital structure is noted for Alivus Life, Cohance Life, Alembic Pharma, Concord Biotech, Natco Pharma, Marksans Pharma, and Akums Drugs, while Jubilant Pharmo has Average capital structure, and Viyash Scientifi has Below Average capital structure.<BR><BR>Return Snapshot: Marksans Pharma has a 1-year return of 91.38%, which is higher than Cohance Life's lowest return of -48.12% and lower than Alivus Life's highest return of 48.66%. Additionally, Natco Pharma and Jubilant Pharmo both have negative six-month returns.

How big is Marksans Pharma?

As of 31st August, Marksans Pharma Ltd has a market capitalization of 14,402.00 Cr, with recent net sales of 3,171.75 Cr and a net profit of 516.75 Cr. The company's shareholder's funds are 3,023.16 Cr, and total assets amount to 3,847.94 Cr.

As of 31st August, Marksans Pharma Ltd has a market capitalization of 14,402.00 Cr, categorizing it as a Small Cap company.<BR><BR>In the latest four quarters, Marksans Pharma reported Net Sales of 3,171.75 Cr and a Net Profit of 516.75 Cr.<BR><BR>For the latest annual period ending in March 2026, the company had Shareholder's Funds amounting to 3,023.16 Cr and Total Assets of 3,847.94 Cr.

Should I buy, sell or hold Marksans Pharma Ltd?

Are Marksans Pharma Ltd latest results good or bad?

Marksans Pharma Ltd's latest Q4 FY26 results are very good, with a net profit of ₹148.13 crores (up 63.59% year-on-year) and revenue of ₹856.11 crores (up 20.84%). The operating margin improved to 22.83%, indicating strong business momentum and effective cost management.

Marksans Pharma Ltd's latest results for Q4 FY26 can be considered very good. The company reported a net profit of ₹148.13 crores, reflecting a significant year-on-year increase of 63.59%. Revenue also saw a strong performance, reaching ₹856.11 crores, which is a 20.84% increase compared to the same quarter last year. <BR><BR>Additionally, the operating margin improved to 22.83%, marking the highest level achieved by the company, indicating enhanced operational efficiency. The profit after tax (PAT) margin also expanded to 17.41%, up from 12.81% in the same quarter last year, showcasing improved profitability alongside revenue growth.<BR><BR>Overall, the financial metrics indicate strong business momentum and effective cost management, making the latest results a positive reflection of Marksans Pharma's performance.

When is the next results date for Marksans Pharma Ltd?

The next results date for Marksans Pharma Ltd is 26 May 2026.

The next results date for Marksans Pharma Ltd is scheduled for 26 May 2026.

How has been the historical performance of Marksans Pharma?

Marksans Pharma has shown consistent growth, with net sales increasing from INR 1,134.21 crore in March 2020 to INR 2,622.85 crore in March 2025, alongside rising profits and total assets. Despite a slight decrease in operating profit margin, the company has maintained positive cash flow from operations while investing in growth.

Answer:<BR>The historical performance of Marksans Pharma shows a consistent growth trajectory in key financial metrics over the years.<BR><BR>Breakdown:<BR>Marksans Pharma's net sales have steadily increased from INR 1,134.21 crore in March 2020 to INR 2,622.85 crore in March 2025, reflecting a strong upward trend. Total operating income has followed a similar pattern, rising from INR 1,000.07 crore in March 2019 to INR 2,622.85 crore in March 2025. The company's total expenditure, excluding depreciation, also grew significantly, reaching INR 2,090.16 crore in March 2025, up from INR 941.96 crore in March 2020. Operating profit (PBDIT) has shown a positive trend, increasing from INR 192.25 crore in March 2020 to INR 599.02 crore in March 2025, although the operating profit margin slightly decreased from 21.06% in March 2024 to 20.31% in March 2025. Profit before tax rose from INR 157.17 crore in March 2020 to INR 503.97 crore in March 2025, while profit after tax increased from INR 120.75 crore to INR 382.62 crore over the same period. The company's total assets have also expanded significantly, from INR 902.03 crore in March 2020 to INR 3,239.63 crore in March 2025, indicating robust growth in its financial position. Cash flow from operating activities has remained positive, with INR 206 crore in March 2025, although cash flow from investing activities has been negative, reflecting investments in growth. Overall, Marksans Pharma has demonstrated strong financial performance and growth across multiple dimensions.

Is Marksans Pharma technically bullish or bearish?

As of November 13, 2025, Marksans Pharma's technical trend is mildly bearish, supported by daily moving averages and Bollinger Bands, despite some mixed signals from weekly indicators.

As of 13 November 2025, the technical trend for Marksans Pharma has changed from sideways to mildly bearish. The current stance is bearish, with key indicators driving this assessment including the daily moving averages showing a mildly bearish trend and the Bollinger Bands indicating a mildly bearish position on both weekly and monthly time frames. Although the weekly MACD and KST are mildly bullish, the overall monthly indicators, including MACD and KST, are mildly bearish, reinforcing the bearish sentiment. The RSI on the weekly is bullish but lacks confirmation from the monthly signal, contributing to a mixed outlook. Overall, the strength of the bearish trend is moderate, influenced by the recent price action and the broader context of the stock's performance compared to the Sensex.

Is Marksans Pharma overvalued or undervalued?

As of October 10, 2025, Marksans Pharma is considered overvalued with a PE ratio of 23.52 and a year-to-date decline of 38.65%, contrasting with the Sensex's 5.58% return.

As of 10 October 2025, Marksans Pharma's valuation grade has moved from fair to expensive, indicating that the company is currently overvalued. The key ratios reflect this assessment, with a PE ratio of 23.52, an EV to EBITDA of 15.66, and a PEG ratio of 4.80. Compared to its peers, Marksans Pharma's valuation appears high; for instance, Sun Pharma has a PE ratio of 34.96, while Cipla is more attractively valued at a PE of 23.39.<BR><BR>Given these metrics, Marksans Pharma is overvalued in the current market context. The company's recent stock performance shows a significant decline year-to-date at -38.65%, contrasting sharply with the Sensex return of 5.58% during the same period, further supporting the notion that the stock may not be a favorable investment at this time.

Who are the top shareholders of the Marksans Pharma?

The top shareholders of Marksans Pharma include Mark Saldanha with 43.8%, Orbimed Asia IV Mauritius FVCI Limited at 10.88%, and various foreign institutional investors owning 22.2%. Additionally, mutual funds hold 3.37%, while individual investors account for 25.77% of the shares, with no pledged promoter holdings reported.

The top shareholders of Marksans Pharma include a mix of promoters and institutional investors. The largest shareholder is Mark Saldanha, who holds 43.8% of the company's shares. Other significant shareholders include Orbimed Asia IV Mauritius FVCI Limited, which holds 10.88%, and various foreign institutional investors (FIIs) who collectively own 22.2% of the company through 135 different entities. Additionally, mutual funds hold 3.37% across 9 schemes, while individual investors account for 25.77% of the shareholding. There are no pledged promoter holdings reported.

Has Marksans Pharma declared dividend?

Marksans Pharma Ltd has declared a 60% dividend, amounting to ₹0.6 per share, with an ex-date of September 17, 2024. While the last 6 months showed a price decline of 25.33%, longer-term returns over 1 to 5 years indicate significant growth, particularly in price returns.

Marksans Pharma Ltd has declared a 60% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 60%<BR>- Amount per share: 0.6<BR>- Ex-date: Sep-17-2024<BR><BR>Dividend Yield: 0.23%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was -25.33%, with a dividend return of 0%, resulting in a total return of -25.33%.<BR><BR>Over the past year, the price return was 67.19%, with a dividend return of 0.39%, leading to a total return of 67.58%.<BR><BR>In the 2-year period, the price return was 183.54%, with a dividend return of 0.66%, culminating in a total return of 184.2%.<BR><BR>For the 3-year period, the price return was 452.34%, with a dividend return of 3.27%, resulting in a total return of 455.61%.<BR><BR>In the last 4 years, the price return was 253.48%, with a dividend return of 1.83%, leading to a total return of 255.31%.<BR><BR>Over the past 5 years, the price return was 698.11%, with a dividend return of 4.81%, culminating in a total return of 702.92%.<BR><BR>Overall, Marksans Pharma has declared a substantial dividend, and while the recent 6-month performance shows a decline, the longer-term returns over 1 to 5 years indicate significant growth, particularly in price returns.